This item is available under a Creative Commons License for non-commercial use only
3. MEDICAL AND HEALTH SCIENCES, Ophthalmology
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD).
Methods. Forty-seven eyes of 47 patients with nv-AMD, and corrected distance visual acuity (CDVA) logMAR 0.7 or better, undergoing intravitreal injections of ranibizumab, were enrolled into this prospective study. Visual function was assessed using a range of psychophysical tests, while mean foveal thickness (MFT) was determined by optical coherence tomography (OCT).
Results. Groupmean (±sd)MFT reduced significantly frombaseline (233±59)) to exit (205±40)) (p = 0.001). CDVA exhibited no change between baseline and exit visits (p = 0.48 and p = 0.31 resp.). Measures of visual function that did exhibit statistically significant improvements (p < 0.05 for all) included reading acuity, reading speed, mesopic and photopic contrast sensitivity (CS), mesopic and photopic glare disability (GD), and retinotopic ocular sensitivity (ROS) at all eccentricities.
Conclusion. Eyes with nv-AMD undergoing intravitreal ranibizumab injections exhibit improvements in many parameters of visual function. Outcome measures other than CDVA, such as CS, GD, and ROS, should not only be considered in the design of studies investigating nv-AMD, but also in treatment and retreatment strategies for patients with the condition.
Sabour Pickett S, Loughman J, Nolan JM, Stack J, Pesudovs K, Meagher KA, Beatty S. Visual Performance in Patients with Neovascular Age Related Macular Degeneration undergoing treatment with intravitreal Ranibizumab. Journal of Ophthalmology, Vol. 2013, 7p. Volume 2013, Article ID 268438, http://dx.doi.org/10.1155/2013/268438